Evidence map›Paper›PMID 41446652›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Combined bone marrow mesenchymal stem cell-derived nanovesicles and low-level laser therapy potentiate proliferation and osteogenesis of bone marrow mesenchymal stem cells.

Jingwei Zhang, Tonghao Yao, Qi Han, Yongqiang Mo, Dailuo Li, Zhengye Zhang, Lihuang Cui, Zhibin Geng, Weitao He, Jingtao Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingwei Zhang *The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Tonghao Yao *The Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Qi Han *The First Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, Shandong, China.
Yongqiang MoThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Dailuo LiThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Zhengye ZhangThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Lihuang CuiThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Zhibin GengThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Weitao HeThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Jingtao ChenThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Xin LiuThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.
Xintao WangThe Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Addressing the persistent challenge of bone defect repair requires innovative bioengineering strategies. Enhancing the biological activity of bone marrow mesenchymal stem cells (BMSCs) is pivotal for effective bone regeneration. This study develops a novel combinatorial bioengineering approach leveraging two distinct biotechnological modalities: low-level laser therapy (LLLT) and bone marrow mesenchymal stem cell-derived nanovesicles (BMSC-NVs). LLLT, a non-invasive biophysical stimulation technique with defined light parameters, is known to prime cellular responses. Concurrently, BMSC-NVs represent an emerging engineered cell-free therapeutic platform with significant promise for tissue regeneration. Thus, we hypothesize that combining LLLT's direct regulatory effects on BMSCs with the bioactive cargo of BMSC-NVs will synergistically enhance BMSC function. This study presents the first evaluation of the combined impact of LLLT and BMSC-NVs on the proliferation and osteogenic differentiation of rat BMSCs Methods: Cell proliferation was quantified using CCK-8 assay, while osteogenic differentiation was assessed through alkaline phosphatase staining, alizarin red staining, and real-time quantitative polymerase chain reaction (osteogenic gene expression). Results: The LLLT+BMSC-NVs combinatorial strategy effectively enhances BMSC proliferation capacity (as indicated by increased OD values measured via CCK-8 assay), ALP activity, mineralized nodule formation, and upregulation of key osteogenic genes (ALP, RUNX2), showing superior effects on both proliferation and osteogenic differentiation compared to individual LLLT or BMSC-NVs treatments. Conclusion: This study proposes a novel cell-free therapeutic paradigm by synergistically integrating LLLT with BMSC-NVs, suggesting an effective bioengineering strategy for bone defect repair.

Indexed as

bone marrow mesenchymal stem cellslow-level laser therapynanovesiclesosteogenic differentiationproliferationsynergistic bioengineering

Identifiers

PMID41446652
PMCPMC12723869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.